Posttherapy topographical nodal status, ypN-site, predicts survival of patients who received neoadjuvant chemotherapy followed by curative surgical resection for non-type 4 locally advanced gastric cancer: supplementary analysis of JCOG1004-A

Gastric Cancer. 2021 Jan;24(1):197-204. doi: 10.1007/s10120-020-01098-w. Epub 2020 Jun 22.


Background: Perioperative treatment is an accepted standard approach for treating locally advanced gastric cancer (LAGC). Histopathological tumor regression with < 10% residual tumor is a globally accepted prognosticator in LAGC patients who received neoadjuvant chemotherapy (NAC) and curative surgery. However, despite a response of the primary tumor, a significant percentage of patients dies from recurrence and identification of those at risk for relapse remains challenging. We re-estimated the value of histopathological tumor regression as a prognosticator alongside other factors, especially posttherapy topographical nodal status, ypN-site.

Patients and methods: Individual patient data including clinicopathological variables were used from the four JCOG trials investigating NAC (JCOG0001, JCOG0002, JCOG0210, JCOG0405) for analyzing prognosticators in patients with curative surgery excluding those with type 4 AGC by univariable and multivariable Cox regression analyses.

Results: Among 85 patients, 5-year overall survival (OS) was 46.0% [95% confidence interval (CI) 35.0-56.4] with a median follow-up of 3.2 years. On univariable analysis, histopathological tumor regression with ≥ 10% residual tumor and ypN-site 2-3 were negatively associated with OS [≥ 10% residual tumor: hazard ratio (HR) 2.60; 95% CI 1.22-5.54; P = 0.014; ypN2-3: HR 3.59; 95% CI 1.60-8.06; P = 0.002). On multivariable analysis, only ypN-site 2-3 was predictive of OS (HR 3.67; 95% CI 1.55-8.69; P = 0.003), whereas histopathological tumor regression with ≥ 10% residual tumor was not (HR 2.24; 95% CI 0.98-5.10; P = 0.055).

Conclusions: ypN-site may have greater impact on OS than histopathological tumor regression in patients who received NAC plus surgery for non-type 4 LAGC.

Keywords: Histopathological tumor regression; Locally advanced gastric cancer; Neoadjuvant chemotherapy; Overall survival; Posttherapy nodal status.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Aged
  • Chemotherapy, Adjuvant / mortality*
  • Clinical Trials, Phase II as Topic
  • Female
  • Gastrectomy / methods
  • Gastrectomy / mortality*
  • Humans
  • Lymph Nodes / pathology
  • Male
  • Middle Aged
  • Neoadjuvant Therapy / mortality*
  • Neoplasm, Residual / mortality
  • Neoplasm, Residual / pathology*
  • Postoperative Period
  • Prognosis
  • Proportional Hazards Models
  • Prospective Studies
  • Stomach / pathology
  • Stomach Neoplasms / mortality
  • Stomach Neoplasms / pathology*
  • Stomach Neoplasms / therapy
  • Survival Rate
  • Treatment Outcome